Movement Disorder Virtual University WE MOVE
Research News
E-MOVE - Research News Service Subscribe to E-MOVE

Search Research News
Any Words All Words Exact Phrase

E-MOVE Archives 1999

ID date title
1 1/18/1999 Amantadine for dyskinesias
2 1/19/1999 Cervical dystonia: mixed results for clozapine
3 1/19/1999 Chronic LD not toxic, may promote neural recovery
4 1/19/1999 PD--GM1 ganglioside effective in double-blind trial
5 1/19/1999 HD: allografts promote integration and functional recovery in primates
6 1/19/1999 PD: Supplement on quality of life
7 1/19/1999 Book on cell transplantation for neurological disorders: table of contents
8 1/19/1999 A selective NAChR agonist potentiates l-dopa in parkinsonian monkeys
9 1/19/1999 Gamma Knife Radiosurgery for Movement Disorders
10 1/19/1999 HD: Guidelines for Genetic Testing
11 1/19/1999 PD treatment symposium: contents
12 1/19/1999 Ropinirole for Early Parkinson's Disease
13 1/19/1999 Selegiline update
14 1/19/1999 ITB: Changes in sexual function and quality of life
15 1/19/1999 Pramipexole for RLS
16 1/19/1999 Aspirin protects against MPTP in mice
17 1/19/1999 CAG-repeat diseases: Nuclear aggregates are not pathogenic; new cell model for HD
18 1/19/1999 PSP update: genetics, natural history, and treatment
19 1/19/1999 PD therapy: Congress posters (1)
20 1/19/1999 PD pathophysiology: Congress posters (2)
21 1/19/1999 Other movement disorders: Congress posters (3)
22 1/19/1999 Genetic Link between PD and ET
23 1/19/1999 MSA update: pathology and treatment
24 1/19/1999 New warnings on Tasmar
25 1/19/1999 Surgery for Dystonia
26 1/19/1999 PD: Genetic Susceptibility Increases Pesticide Risk
27 1/19/1999 Tardive dyskinesia and dystonia: Natural history studies
28 1/19/1999 BTX-A vs phenol for spastic foot
29 1/19/1999 Pergolide for RLS
30 1/19/1999 PD: Neuroprotection from phospholipase knockouts, nicotine
31 1/19/1999 PLMS, RLS and ADHD
32 1/19/1999 Increased spasticity from IFNB-1b in progressive MS
33 1/19/1999 DHEC vs lisuride for PD
34 1/19/1999 Plasma exchange relieves BTX resistance
35 1/19/1999 Rhizotomy for spasticity--update
36 4/14/1999 PD: Vitamin D reduces fracture risk
37 4/14/1999 PD: Inheritance not a significant factor in late-onset disease
38 4/14/1999 Rett syndrome update: Genetics and diagnosis
39 4/14/1999 Cerebral palsy: Equine-movement therapy; crouch gait evaluation and treatment
40 4/14/1999 Tourette's syndrome: family history effects, new treatment
41 4/14/1999 RLS: Sustained-release levodopa improves sleep
42 4/14/1999 MSA update: Diagnosis, imaging, environmental toxins
43 4/14/1999 PD: Clozapine for psychosis; neuroleptic malignant syndrome susceptibility
44 4/14/1999 PD etiology: Genetics, CSF cytotoxicity, family risks
45 4/14/1999 BTX-A biochemistry: Recovery of original terminals; journal special issue
46 4/14/1999 Dystonia genetics
47 4/14/1999 Dystonia physiology; surgical treatment
48 4/23/1999 PD: APOE genotype, familial vs. sporadic features (AAN report)
49 4/23/1999 RLS update: Pathophysiology, comorbidity, treatment
50 4/23/1999 Dystonia genetics (AAN report)
51 4/23/1999 RLS: Abnormal iron, normal dopamine metabolism (AAN report)
52 4/23/1999 Spasticity drug therapy (AAN report)
53 4/23/1999 Sydenham's chorea and chorea gravidarum (AAN report)
54 4/23/1999 Parkinsonism: treatment of non-motor complications (AAN report)
55 4/23/1999 PD: Physical and occupational therapies (AAN report)
56 4/26/1999 Dystonia pathophysiology and comorbidity (AAN report)
57 4/26/1999 PD: Pramipexole (AAN report)
58 4/26/1999 PD: Glutamate antagonists (AAN report)
59 4/26/1999 Dopamine agonists: Adverse effects (AAN report)
75 4/30/1999 PD: Fetal transplants (AAN report)
76 4/30/1999 Dystonia surgery (AAN report)
77 4/30/1999 BTX-A current bulk toxin vs. original (AAN report)
78 4/30/1999 BTX-B for cervical dystonia (AAN report)
60 6/10/1999 Myoclonus dystonia gene candidate
61 6/10/1999 PD: Longitudinal PET study of twins indicates inheritance
62 6/10/1999 PD: Estrogen; drug interactions
63 6/10/1999 Experimental drugs for PD
64 6/10/1999 Rett Syndrome treatments
65 6/10/1999 Hypotheses of disease mechanisms for PD, HD
66 6/10/1999 Baclofen and BTX-A for tics in Tourette's Syndrome
67 6/11/1999 Friedreich's ataxia: Disease mechanisms
68 6/11/1999 Myoclonus: Epidemiology, and treatment for sleep disruption
74 6/14/1999 HD: New transgenic mouse model implicates calcium
79 6/21/1999 HD: New transgenic mouse model implicates calcium
80 6/21/1999 Myoclonus: Epidemiology and treatment for sleep disorder
81 6/21/1999 Friedreich's ataxia: Disease mechanisms
82 7/1/1999 HD: role of caspase-1, normal function of htt, treatment
83 7/2/1999 Surgery for adductor spasmodic dysphonia
84 7/6/1999 Toxins'99 announcement
85 7/8/1999 New on the WE MOVE Web Site....
86 7/17/1999 Manganese neurotoxicity: Journal contents
87 7/19/1999 Glial cells, glutathione, and oxidative stress
88 7/19/1999 Announcement: PD Congress Research Updates
89 7/20/1999 Cannabinoid receptors modulate D2 receptor effects
90 7/20/1999 D1 receptors in PD
91 7/25/1999 Entacapone and Tolcapone (PD Congress report)
92 7/31/1999 Tolcapone's effect on mitochondria is reduced by serum protein (PD Congress report)
582 8/1/1999 Early ropinirole reduces dyskinesias (PD Congress report)
583 8/1/1999 Endogenous neurotoxins and neuroprotectants (PD Congress report)
586 8/1/1999 Cannabinoids in parkinsonism (PD Congress report)
584 8/1/1999 Pathophysiology of the basal ganglia in PD (PD Congress report)
585 8/1/1999 Depression is a major determinant of quality of life in PD (PD Congress report)
93 8/8/1999 Cabergoline (PD Congress report)
94 8/8/1999 New and Experimental Treatments (PD Congress report)
95 8/13/1999 BTX Update
96 8/19/1999 CAG repeat diseases: Journal contents
97 8/24/1999 Clozapine for dystonia
98 8/24/1999 Gabapentin for essential tremor
99 8/26/1999 Ropinirole vs Bromocriptine
100 8/27/1999 Sublingual sustained-release apomorphine for PD fluctuations
101 8/30/1999 NIH Outlines Plan for PubMed Central
102 8/31/1999 Amantadine update
103 8/31/1999 Electrophysiology of BTX-A and Phenol in Spasticity
104 9/2/1999 MPTP mechanism; CAG neuroprotection
105 9/8/1999 PD: Sialorrhea, Hypophonia
106 9/8/1999 A Rating Scale for Dystonia
107 9/8/1999 New Marker for Nigral Cells Maps PD Cell Loss
108 9/9/1999 Transplantion in models of PD and SCA-1
109 9/9/1999 Psychogenic Tremor; Budipine for PD Tremor
110 9/10/1999 Abnormal Neuronal Activity in Dystonia
111 9/13/1999 Announcement: Upcoming PD Web Chat
112 9/14/1999 Announcement: PD Web pages updated and expanded
113 9/16/1999 Estrogens in PD
114 9/16/1999 Basal ganglia physiology
115 9/24/1999 PD and HD: Genetic Treatment Strategies
116 10/1/1999 Symptomatic Effect of Lamotrigine in HD
117 10/1/1999 Second Announcement and Program Update: Toxin99
118 10/1/1999 New Precautions for Mirapex
119 10/1/1999 Early PD Therapy: Pergolide; CR Levodopa/carbidopa
120 10/6/1999 PSP Update: Heredity, Pathology, Treatment
121 10/7/1999 Stiff Man Syndrome
122 10/8/1999 Rett Syndrome: Gene Identified; Cardiac Abnormalities
123 10/11/1999 Tardive Dyskinesia Treatment
124 10/11/1999 Dystonia: Metal Accumulation in the Basal Ganglia
125 10/13/1999 Announcement: WE MOVE Web Site Update
126 10/22/1999 ATP production is decreased in Friedreich Ataxia
127 10/22/1999 Spasticity: Alcohol Neurolysis, Scale Reliability, Pain
128 10/25/1999 HD: Gene Findings, Cancer Incidence
129 10/28/1999 PSP: Cerebellar Input Involvement
130 10/28/1999 Pallidotomy for Dystonia
131 10/31/1999 Announcement: Toxin99 update
132 11/1/1999 Botlinum Toxin Type B for Cervical Dystonia
133 11/1/1999 Entacapone Approved by FDA
134 11/4/1999 MPTP: Chronic neurodegeneration from acute exposure; role for apoptotic protein
135 11/8/1999 PLMD in Children; RLS Electrophysiology
136 11/8/1999 Tourette Syndrome: Co-morbidity of Autism; Neurophysiology
137 11/8/1999 PD: Memantine; Patient Profile
138 11/17/1999 BOTOX® "old" vs. "current" lots (Toxin99 report)
139 11/17/1999 Dysport® Dosing Studies
140 11/17/1999 Treatment of Cervical Dystonia
141 11/18/1999 Treatment of Hyperhidrosis
142 11/18/1999 BTX-A Dose for Anhydrosis: Qualitative and Quantitative Analyses
143 11/21/1999 BTX-A for Orthopedic Indications (Toxin99 report)
144 11/21/1999 BTX-A for Freezing of Gait, Sialorrhea, Constipation in Parkinsonism (Toxin99 report)
145 11/22/1999 BTX-A for Tension-Type Headache (Toxin99 report)
146 11/23/1999 BTX-A for Migraine (Toxin99 report)
147 11/24/1999 Dyskinesias (Journal Supplement)
148 11/29/1999 BTX-A for Cerebral Palsy (Toxin99 report)
149 12/6/1999 BTX-A treatment failure (Toxin99 report)
150 12/6/1999 Non-motor effects of BTX (Toxin99 report)
151 12/12/1999 Surgery for Spasticity
152 12/12/1999 BTX-A Biochemistry: Persistence of Effect
153 12/25/1999 BTX-A vs. B: Spread of Toxin (Toxin99 report)
154 12/26/1999 PD Dyskinesias: Amantadine Follow-up, GPi activity
155 12/26/1999 Surgery for Essential Tremor
156 12/26/1999 PD Drugs: Adverse Effects
157 12/29/1999 PD Surgery: Single-Blind Pallidotomy, Apomorphine Test

 
All contents copyright © WE MOVE 2013. This page last modified 3/5/2008.